33 results about "Ampelopsin" patented technology

The invention discloses five crystalline form substances of dihydromyricelin (of which the chemical name is 3,5,7,3',4',5'-hexahydroxy-2,3-dihydroflavonol and the English name is dihydromyricelin or ampelopsin). The spatial configuration of dihydromyricelin is characterized by virtue of colorimetry-polarimetry and high-performance liquid-phase chiral separation methods. By virtue of solid-state analytical technologies including a powder X-ray diffraction (XRD), differential scanning calorimetry (DSC), thermal gravimetric analysis (TGA), a Karl Fischer titration and Fourier transform-attenuated total reflectance (FT-ATR) infrared spectroscopy, the crystalline forms of dihydromyricelin are characterized. The polymorph screening of dihydromyricelin is of important significance for the development of processes of active pharmaceutical ingredients, the development of dosage forms such as solid preparation, semi-solid preparation and suspension and quality control.

The invention relates to the use of ampelopsin in preparation of angiogenesis inhibitor drug, wherein the suppression function of ampelopsin to propagation of blood vessel endothelial cells is reviewed, the suppression function of ampelopsin to synthesis and secretion of VEGF, bFGF by human hepatoma cells is also examined, test results show that ampelopsin has suppression function to propagation of blood vessel endothelial cells, and also suppression action to the synthesis and secretion of VEGF and bFGF.

The invention discloses the use of ampelopsin in the preparation of healthcare food and medicaments for protecting vascular endothelial cells. In the invention, purified ampelopsin or unpurified ampelopsin-containing extract is prepared into pharmaceutically allowable preparations for oral taking, injection or external application. The ampelopsin protects the vascular endothelial cells by reducing peroxidation of lipid, resisting oxidative damage and other actions, so as to prevent and treat cardiovascular and cerebrovascular diseases caused by endothelial cell injury, such as atherosclerosis, hypertension and cardiac-cerebral thrombosis.

The invention relates to a ampelopsin derivative, wherein R1-R5 are represented as formula II or H, and R1-R5 are not all as H. The invention further relates to the synthesis method of the derivative and relative application for preparing anti-cancer drug.

The invention relates to the technical field of agricultural cultivation, in particular to an ampelopsin grossedentata light matrix seedling tray cuttage seedling method.The method includes the steps that grass carbon, perlite and vermiculite are evenly mixed and placed into a seedling tray; one-year strong fresh tender branches which are free of dehydration, diseases and pests and have leaves are selected, and stems are pruned; the pruned ampelopsin grossedentata stems are placed into a rooting powder aqueous solution to be soaked; the processed ampelopsin grossedentata branches are inserted into the light matrix seedling tray, kept vertically upwards and placed in a greenhouse after cuttage to be maintained; after the ampelopsin grossedentata branches sprout and 90% of the stems root, water-soluble fertilizer is applied; after roots of ampelopsin grossedentata plants overgrow and the length of veins is larger than or equal to 20 cm, ampelopsin grossedentata is harvested; ampelopsin grossedentata light matrix seedling tray cuttage seedling is finished.The seedling tray cuttage survival rate can reach 90% or above, scions are saved compared with land seedling cuttage, ampelopsin grossedentata roots in one month, seedlings are obtained and harvested in three months, the survival rate of transplanting in fields is up to 95%, and the advantages of land cuttage are incomparable to those of the method.

The invention relates to a method for detecting gallic acid and ampelopsin in tea tincture. The method comprises performing determination through a liquid chromatography tandem mass spectrometry and performing calibration through an external standard method. The method for detecting the gallic acid and the ampelopsin in the tea tincture has the advantage s of being short in detecting time, simple in operation, high in sensitivity and recovery rate, good in repeatability and the like. Chromatographic conditions in the method enable the chromatographic peaks of the gallic acid and the ampelopsin to be well separated from those of impurities and to obtain good linearity ranges with limit of detection of 0.002 mu g/mL, the recovery rate of the gallic acid is between 91.3% and 109.2%, the recovery rate of the ampelopsin is between 84.1% and 97.8%, and the relative standard deviations of the detecting results of samples are all smaller than 5%.

The invention discloses application of ampelopsin for preparing a medicament for treating acne abscess, ulcer fester and piles, and the medicament can be prepared into pharmaceutically accepted dosage forms for external use, oral administration and injection.

The invention belongs to the field of pharmaceutical preparations and relates to an ampelopsin grossedentata total flavonoid solid lipid nanoparticle and a preparation method. The solid lipid nanoparticle takes solid natural or synthetical lipoid as a carrier and comprises the following raw materials in percentage by weight: 0.3-0.7% of ampelopsin grossedentata total flavonoids, 4-12% of a surfactant and the balance of water, wherein a drug-lipid ratio is 1:3-1:12. The preparation method employs a fusion-ultrasound method or a high-pressure homogenization method. Encapsulation efficiency and drug loading capacity of the ampelopsin grossedentata total flavonoids can be improved by selecting the appropriate solid lipid and an emolsifier and optimizing a raw material proportion; a particle size is reduced; and stability, bioavailability and targeting ability of the nanoparticle are improved. The ampelopsin grossedentata total flavonoid solid lipid nanoparticle with the small particle sizeand the higher encapsulation efficiency is prepared by the simple, convenient and operation controllable fusion-ultrasound method and shows a slow release characteristic; and a novel dosage form is provided for development and clinical application of the ampelopsin grossedentata total flavonoids.

The present invention discloses an application of ampelopsin in preparation of vascular endothelial cell protection health food or drugs, wherein purified ampelopsin or an unpurified ampelopsin-containing extract can be adopted to prepare a pharmaceutically acceptable oral formulation, a pharmaceutically acceptable injection formulation or a pharmaceutically acceptable external application formulation, and the ampelopsin provides a vascular endothelial cell protection function through lipid peroxidation reduction, oxidative damage resistance and other effects so as to prevent and treat cardiovascular and cerebrovascular diseases caused by vascular endothelial cell damage, wherein the diseases comprise atherosclerosis, high blood pressure, heart and cerebral thrombosis, and the like.

The invention discloses a method for improving biological activity of flavonoid compounds, belongs to the technical field of medicines, particularly relates to the technical field of pharmaceutical compositions such as pharmaceutical dosage forms and preparations, and relates to a method for improving or improving oral absorption bioavailability of ampelopsin. The preparation is characterized in that the ampelopsin and an auxiliary material with a metabolic enzyme inhibition effect are jointly prepared into the preparation, and the concentration of the ampelopsin in plasma in a body can be effectively improved or increased, so that the oral curative effect of the ampelopsin is improved. The invention also relates to a method for improving the biological activity of the flavonoid compound. The invention has excellent technical effects as described in the specification.

The invention relates to a traditional Chinese medicine for treating prosopoplegia. The traditional Chinese medicine is prepared from following raw medicinal materials comprising, by weight, 10 parts of keiske wormwood, 15 parts of tinospora sinensis (Lour.) Merr., 8 parts of Chinese starjasmine stem, 1 part of ampelopsin grossedentata, 80 parts of herba corydalis impatiens, 3 parts of cimicifuga acerina and 6 parts of licorice. A clinical experiment result proves that the traditional Chinese medicine in the invention can treat the prosopoplegia safely and effectively.

The invention discloses an ampelopsin pro-drug and a preparing method and application thereof. The general formula (I) of the ampelopsin pro-drug is:, and compared with ampelopsin, the compound increases the water solubility obviously. In the preparing method, poisonous organic solvent is not used, all the solvents can be recycled, and other non-environmental-friendly reagents are not used. The ampelopsin pro-drug compound can be prepared into various dosage forms in pharmacy, including injection, tablets, capsules and granules, which is especially suitable for preparing powder-injection for injection.